Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Androgen receptor antagonist

DRUG CLASS:

Androgen receptor antagonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	histrelin acetate + nilutamide Sensitive: A2 - Guideline histrelin acetate + nilutamide Sensitive : A2	histrelin acetate + nilutamide Sensitive: A2 - Guideline histrelin acetate + nilutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	goserelin acetate + nilutamide Sensitive: A2 - Guideline goserelin acetate + nilutamide Sensitive : A2	goserelin acetate + nilutamide Sensitive: A2 - Guideline goserelin acetate + nilutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	triptorelin + nilutamide Sensitive: A2 - Guideline triptorelin + nilutamide Sensitive : A2	triptorelin + nilutamide Sensitive: A2 - Guideline triptorelin + nilutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	leuprolide acetate + nilutamide Sensitive: A2 - Guideline leuprolide acetate + nilutamide Sensitive : A2	leuprolide acetate + nilutamide Sensitive: A2 - Guideline leuprolide acetate + nilutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	EPI-7386 Sensitive: B - Late Trials EPI-7386 Sensitive : B	EPI-7386 Sensitive: B - Late Trials EPI-7386 Sensitive : B
AR positive	Breast Cancer	AR positive	Breast Cancer	GT0918 Sensitive: C2 – Inclusion Criteria GT0918 Sensitive : C2	GT0918 Sensitive: C2 – Inclusion Criteria GT0918 Sensitive : C2
AR F877L	Prostate Cancer	AR F877L	Prostate Cancer	apalutamide Resistant: C3 – Early Trials apalutamide Resistant : C3	apalutamide Resistant: C3 – Early Trials apalutamide Resistant : C3
AR overexpression	Triple Negative Breast Cancer	AR overexpression	Triple Negative Breast Cancer	TAK 700 Sensitive: C3 – Early Trials TAK 700 Sensitive : C3	TAK 700 Sensitive: C3 – Early Trials TAK 700 Sensitive : C3
AR T878A	Prostate Cancer	AR T878A	Prostate Cancer	apalutamide Resistant: C3 – Early Trials apalutamide Resistant : C3	apalutamide Resistant: C3 – Early Trials apalutamide Resistant : C3
PTEN expression	Prostate Cancer	PTEN expression	Prostate Cancer	leuprolide acetate + apalutamide Sensitive: C3 – Early Trials leuprolide acetate + apalutamide Sensitive : C3	leuprolide acetate + apalutamide Sensitive: C3 – Early Trials leuprolide acetate + apalutamide Sensitive : C3
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	apalutamide Sensitive: C3 – Early Trials apalutamide Sensitive : C3	apalutamide Sensitive: C3 – Early Trials apalutamide Sensitive : C3